NIH-funded trial to evaluate stem cell therapy in heart failure patients
This article was originally published in Clinica
Executive Summary
Angioblast Systems, the US-based sister company of Australian regenerative medicine firm Mesoblast, has begun a US trial of Revascor, Mesoblast's cardiac stem cell therapy.